GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis.
GPR65 as a potential immune checkpoint regulates the immune microenvironment according to pan-cancer analysis.
复制标题
DOI：
10.1016/j.heliyon.2023.e13617
复制
发表时间：
2023-03
期刊：
影响因子：
4
通讯作者：
Sun, Junhong
中科院分区：
文献类型：
--
作者：
Wang, Liangliang;Sun, Lele;Sun, Hao;Xing, Yunhong;Zhou, Shidong;An, Guoshuai;Li, Jian;Ren, Kang;Sun, Junhong
据报道，抑制GPR65可有效治疗某些癌症。然而，GPR65在各种癌症中的作用仍然未知。我们使用多个数据库，包括TCGA，GTEX，BioGPS，HPA，cBioPortal和GeneCards，对GPR65进行了详尽的泛癌症分析。发现GPR65在各种癌症中差异表达，并与肿瘤突变负荷（TMB）、微卫星不稳定性（MSI）和倍性相关，在肿瘤微环境（TME）中发挥关键作用。它与某些癌症中Th17细胞以及Th1和Th2细胞的发育密切相关。我们的研究结果表明，GPR65的表达与临床预后、突变和免疫细胞浸润密切相关。它被揭示为患者预后的指标以及可能的免疫调节作用。GPR65作为一种新的免疫检查点，有望成为肿瘤免疫治疗的靶点。
It has been reported that inhibition of GPR65 may be effective for the treatment of certain cancers. Nevertheless, the role of GPR65 in various cancers remains unknown. We conducted an exhaustive pan-cancer analysis of GPR65 using multiple databases, including TCGA, GTEx, BioGPS, HPA, cBioPortal, and GeneCards. GPR65 was found to be differentially expressed in various cancers and linked to tumor mutational burden (TMB), microsatellite instability (MSI), and Ploidy, playing a key function in the tumor microenvironment (TME). It is closely linked to the development of Th17 cells as well as Th1 and Th2 cells in certain cancers. Our findings indicate that the expression of GPR65 is highly linked with clinical prognosis, mutations, and immune cell infiltration. It was revealed as an indicator of patient prognosis as well as a possible immunomodulatory role. As a possible new immunological checkpoint, GPR65 could be a target for tumor immunotherapy.
登录
查看更多内容
影响因子：
7.3
作者：
Gao J;Aksoy BA;Dogrusoz U;Dresdner G;Gross B;Sumer SO;Sun Y;Jacobsen A;Sinha R;Larsson E;Cerami E;Sander C;Schultz N
通讯作者：
Schultz N
影响因子：
64.8
作者：
Li X;Kim Y;Tsang EK;Davis JR;Damani FN;Chiang C;Hess GT;Zappala Z;Strober BJ;Scott AJ;Li A;Ganna A;Bassik MC;Merker JD;GTEx Consortium;Laboratory, Data Analysis &Coordinating Center (LDACC)—Analysis Working Group;Statistical Methods groups—Analysis Working Group;Enhancing GTEx (eGTEx) groups;NIH Common Fund;NIH/NCI;NIH/NHGRI;NIH/NIMH;NIH/NIDA;Biospecimen Collection Source Site—NDRI;Biospecimen Collection Source Site—RPCI;Biospecimen Core Resource—VARI;Brain Bank Repository—University of Miami Brain Endowment Bank;Leidos Biomedical—Project Management;ELSI Study;Genome Browser Data Integration &Visualization—EBI;Genome Browser Data Integration &Visualization—UCSC Genomics Institute, University of California Santa Cruz;Hall IM;Battle A;Montgomery SB
通讯作者：
Montgomery SB
影响因子：
7.4
作者：
Justus, Calvin R.;Sanderlin, Edward J.;Yang, Li V.
通讯作者：
Yang, Li V.
影响因子：
9.3
作者：
Chen F;Zhuang X;Lin L;Yu P;Wang Y;Shi Y;Hu G;Sun Y
通讯作者：
Sun Y
影响因子：
4.3
作者：
Choi, JW;Lee, SY;Choi, YW
通讯作者：
Choi, YW